Vicore Pharma Holding AB (publ) (STO:VICO)

Sweden flag Sweden · Delayed Price · Currency is SEK
11.62
-0.68 (-5.53%)
Oct 10, 2025, 5:29 PM CET
-5.53%
Market Cap2.73B
Revenue (ttm)7.74M
Net Income (ttm)-370.92M
Shares Out234.61M
EPS (ttm)-1.87
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume935,668
Average Volume917,710
Open12.38
Previous Close12.30
Day's Range11.62 - 12.52
52-Week Range6.09 - 14.10
Beta0.40
RSI47.99
Earnings DateNov 5, 2025

About Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Pha... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 29
Stock Exchange Nasdaq Stockholm
Ticker Symbol VICO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.